Form 4: Biote Corp. CFO Awarded Stock Options
SEC Form 4
Robert Charles Peterson, CFO of Biote Corp., received stock options for 350,000 shares of Class A Common Stock on April 1, 2025.
Summary
- Robert Charles Peterson, the Chief Financial Officer of Biote Corp., was granted employee stock options on April 1, 2025.
- The options give Peterson the right to buy 350,000 shares of Class A Common Stock at an exercise price of $3.63 per share.
- The options vest over time, with 25% vesting on April 1, 2026, and the remaining 75% vesting in 36 equal monthly installments thereafter, contingent upon Peterson's continued service.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a common practice and generally viewed favorably as it aligns management's interests with shareholders. There are no explicit negative indicators.
Positives
- The granting of stock options aligns the CFO's interests with those of the shareholders, incentivizing him to improve the company's performance.
- The vesting schedule encourages long-term commitment from the CFO.
Risks
- The value of the stock options is dependent on the future performance of Biote Corp.'s stock price.
- If Peterson leaves the company before the options are fully vested, he will forfeit the unvested portion.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options to incentivize their executives.
- The vesting schedule and exercise price are typical for stock option grants of this nature.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CFO to improve company performance.
- Employees may see this as a positive sign of investment in leadership.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of the stock option grant. |
| 04/01/2025 | Earliest transaction date. |
| 04/01/2026 | 25% of the shares subject to the option shall vest. |
| 03/31/2035 | Expiration date of the stock options. |
| 04/02/2025 | Date of signature. |
Keywords
stock options, Biote Corp, CFO, Robert Charles Peterson, equity compensation, BTMD, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.